San Francisco CEO
January 11 - 12, 2025
Four Seasons, San Francisco
Longwood Healthcare Leaders San Francisco CEO brings together leading biopharma CEOs, heads of R&D, top academic researchers, and life science investors the weekend prior to the JP Morgan Healthcare Conference for off-the-record discussion, held at the Four Seasons San Francisco. Join us for an intimate event with leaders in the industry.
_edited.png)
Featured Speakers
Academic & Regulatory Leaders
BioPharma CEOs
R&D and TA Heads
BD & Strategy Leaders
Investor Perspectives
Agenda
January 11, 2025
7:00 am
REGISTRATION & NETWORKING BREAKFAST
7:30 am
LONGWOOD FUND INTRODUCTION
Vikas Goyal, Venture Partner, Longwood Fund
8:00 am
BIG BIOPHARMA PIPELINE SOURCING
Wendy Bartie, SVP, US Oncology & Hematology, BMS
Paris Panayiotopoulos, Senior Managing Director, Blackstone Life Sciences
David Redfern, President, Corporate Development, GSK
8:30 am
ADVANCING THE TRANSLATION OF BIOMEDICAL RESEARCH
Kara Carter, EIR, Evotec
Theresa Heah, CEO, Paratus Sciences
9:00 am
FIRESIDE CHAT: PHARMA R&D LEADERSHIP
Eliav Barr, CMO & Head, Global Clinical Development, Merck Research Laboratories
9:20 am
DEVELOPING GLOBAL PARTNERSHIPS
Meeta Chatterjee, Chief Strategy Officer, Sun Pharma
Philippe Lopes-Fernandes, CBO, Ipsen
Thomas Mehrling, CEO, Helix BioPharma
Zhen Su, CEO, Marengo Therapeutics
Moderator: Daniel Palmacci, President, Cell & Gene, Lonza
9:55 am
NETWORKING BREAK
10:20 am
ACCELERATING DRUG DEVELOPMENT
Anirvan Ghosh, CEO, Unity Biotechnology
Carl Hansen, CEO, AbCellera
Shiva Malek, Global Head, Oncology, Novartis BioMedical Research
Phil Vickers, CEO, Solu Therapeutics
Moderator: Lisa Ricciardi, CEO, Cognition Therapeutics
10:50 am
R&D COLLABORATION
Wolfram Carius, EVP, Cell & Gene Therapy, Bayer Pharmaceuticals
Ruxandra Draghia-Akli, EVP, Head, R&D, Novavax
Julie Gerberding, CEO, Foundation for the NIH
Ryan Richardson, Chief Strategy Officer, BioNTech
Moderator: Ken Drazan, CEO, ArsenalBio
11:20 am
IMPACT & IMPORTANCE OF COMPANY CULTURE
Meg Alexander, President & COO, Ovid Therapeutics
Jeb Keiper, CEO, Nimbus Therapeutics
Mathai Mammen, CEO, Parabalis Medicines
Joanne Smith-Farrell, CEO, Be Bio
11:50 am
FIRESIDE CHAT
Teresa Graham, CEO, Roche Pharma
Marc Tessier-Lavigne, CEO, Xaira
12:10 pm
NETWORKING LUNCHEON
1:00 pm
DRUG DISCOVERY SCIENCES
Dee Datta, CEO, Switch Therapeutics
JJ Kang, CEO, Appia Bio
John Lepore, CEO, ProFound Therapeutics
Dominique Verhelle, CEO, NextRNA Therapeutics
Moderator: Yiannis Kiachopoulos, CEO, Causaly
1:30 pm
ADVANCES IN CLINICAL TRIALS
Michael Amoroso, CEO, Precision Biosciences
Jim Wooldridge, CMO, Immunitas Therapeutics
Moderator: Chris Smyth, President, ICON Biotech
2:00 pm
INNOVATIVE COMMERCIAL MODELS
Kabir Nath, CEO, COMPASS Pathways
Ram Palanki, CCO, REGENXBIO
Moderator: Steve Blaising, CEO, Brain Surgery Worldwide
2:30 pm
M&A AND DEAL-MAKING LANDSCAPE
Jennifer Cayer, CBO, Pulmocide
Susan Hill, CEO, Mestag Therapeutics
Moderator: Matthias Müllenbeck, SVP, Global Head, BD & Alliance Management, EMD Serono
3:00 pm
NETWORKING BREAK
3:30 pm
REGULATORY KEYNOTE
Peter Marks, Director, CBER, FDA
4:00 pm
RARE DISEASE INNOVATION
Peter Ghoroghchian, CEO, Latus Bio
Shalini Sharp, former CFO, Ultragenyx
Moderator: Preston Taylor, CFO, Greater Than One
4:30 pm
FINANCING INNOVATION
Lovisa Afzelius, General Partner, Flagship Pioneering
Frank Nestle, Partner & CEO, Deerfield Discovery and Development
Vijay Pande, General Partner, a16z
Moderator: Jonas Grossman, Managing Partner & President, Chardan
5:00 – 7:00 pm
COCKTAIL RECEPTION
January 12, 2025
7:00 am
REGISTRATION & NETWORKING BREAKFAST
7:30 am
LONGWOOD FUND INTRODUCTION
Aleks Radovic-Moreno, Partner, Longwood Fund
8:00 am
DRIVING PRODUCTIVITY IN R&D
Nenad Grmusa, CEO, DEM Bio
Chris Loose, CEO, Progentos
Moderator: Joel Schneider, CEO, Carbon Biosciences
8:30 am
POLICY IMPACT ON INNOVATION
Hal Barron, CEO, Altos Labs
Piraye Beim, CEO, Celmatix
Joshua Sharfstein, Vice Dean & Professor, Health Policy & Management, Johns Hopkins
9:00 am
PLATFORM TO PIPELINE
Keith Gottesdiener, CEO, Prime Medicine
Larry Hamann, CEO, Interdict Bio
Sek Kathiresan, CEO, Verve Therapeutics
Daphne Koller, CEO, Insitro
Moderator: Harvey Berger, CEO, Kojin Therapeutics
9:30 am
ALIGNING WITH REGULATORY AUTHORITIES
Steve Hahn, CEO, Harbinger Health; former Commissioner, FDA
Thomas Lonngren, former Executive Director, EMA
Chrystal Louis, CMO, TScan Therapeutics
10:00 am
NETWORKING BREAK
10:20 am
FIRESIDE CHAT
George Yancopoulos, President & CSO, Regeneron
10:40 am
PATIENT-CENTRIC DEVELOPMENT
Jessica Ballinger, CEO, Lyndra Therapeutics
Lyn Baranowski, CEO, Avalyn Pharma
Lynn Durham, CEO, Stalicla
Anne Wojcicki, CEO, 23andMe
Moderator: Ariel Katz, CEO, H1
11:10 am
ACCESSING TECHNOLOGY TO ADVANCE THE PIPELINE
Derek Adams, CEO, Stellular Bio
Mark Kotter, CEO, bit.bio
Jonathan Powell, Head, Development, Calico Labs
Uli Stilz, Founder & Head, Bio Innovation Hub, Novo Nordisk
11:40 am
BIG BIOPHARMA R&D
Tadaaki Taniguchi, CMO, Astellas
12:10 pm
NETWORKING LUNCHEON
1:00 pm
FIRESIDE CHAT
Jay Bradner, EVP, R&D, & CSO, Amgen
Lloyd Minor, Dean, Stanford School of Medicine
1:30 pm
EXTERNAL INNOVATION, IN-LICENSING AND SPIN-OUTS
Nouhad Husseini, SVP, Head, BD & Corporate Strategy, Regeneron
Vikram Karnani, CEO, Collegium Pharma
Bruce Rogers, President, Morphic Therapeutic
Beth Shafer, CBO, Scholar Rock
Moderator: Navneet Kumar, CEO, Myra EB Systems
2:00 pm
UNITING THE BIOPHARMA INDUSTRY TO HELP PATIENTS
Jeremy Levin, CEO, Ovid Therapeutics
2:30 pm
NETWORKING BREAK
3:00 pm
FIRESIDE CHAT
Stefan Oelrich, CEO, Bayer Pharmaceuticals
3:20 pm
THE NEXT WAVE OF TARGETED THERAPIES
Maria Fardis, CEO, Lassen Therapeutics
Mat Pletcher, CSO, Weaver
Ioannis Sapountzis, Corporate SVP & Global Head, Therapeutic Areas, Boehringer Ingelheim
Moderator: John Alam, CEO, CervoMed
3:50 pm
INVESTMENT OUTLOOK
Ansbert Gadicke, Managing Partner, MPM BioImpact
Ursheet Parikh, Partner, Mayfield
Moderator: Aleks Radovic-Moreno, Partner, Longwood Fund
Speaking Faculty
.png)
.png)
